WO1997041206A3 - Von willebrand factor multimerase - Google Patents

Von willebrand factor multimerase Download PDF

Info

Publication number
WO1997041206A3
WO1997041206A3 PCT/EP1997/002131 EP9702131W WO9741206A3 WO 1997041206 A3 WO1997041206 A3 WO 1997041206A3 EP 9702131 W EP9702131 W EP 9702131W WO 9741206 A3 WO9741206 A3 WO 9741206A3
Authority
WO
WIPO (PCT)
Prior art keywords
multimerase
von willebrand
willebrand factor
leu
vwf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1997/002131
Other languages
French (fr)
Other versions
WO1997041206A2 (en
Inventor
Miha Furlan
Bernhard Laemmle
Hans-Peter Schwarz
Peter Turecek
Johann Eibl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT76996A external-priority patent/AT404359B/en
Priority claimed from AT77096A external-priority patent/AT404554B/en
Application filed by Immuno AG filed Critical Immuno AG
Priority to EP97921765A priority Critical patent/EP0907724B1/en
Priority to DE69737500T priority patent/DE69737500T2/en
Priority to CA2253246A priority patent/CA2253246C/en
Priority to JP9538572A priority patent/JP2000508918A/en
Priority to DK97921765T priority patent/DK0907724T3/en
Publication of WO1997041206A2 publication Critical patent/WO1997041206A2/en
Publication of WO1997041206A3 publication Critical patent/WO1997041206A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Paper (AREA)

Abstract

There is disclosed a purified multimerase having an indirect and a direct proteolytic activity, which converts vWF having a singlet structure to vWF having a satellite structure and is active in the presence of the serine protease inhibitor DFP or the calpain protease inhibitor Z-Leu-Leu-Tyr-CHN2, as well as a method of preparing the multimerase according to the invention.
PCT/EP1997/002131 1996-04-29 1997-04-25 Von willebrand factor multimerase Ceased WO1997041206A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP97921765A EP0907724B1 (en) 1996-04-29 1997-04-25 Von willebrand factor multimerase
DE69737500T DE69737500T2 (en) 1996-04-29 1997-04-25 Purified multimerase
CA2253246A CA2253246C (en) 1996-04-29 1997-04-25 Purified multimerase
JP9538572A JP2000508918A (en) 1996-04-29 1997-04-25 Purified multimerase
DK97921765T DK0907724T3 (en) 1996-04-29 1997-04-25 Von Willebrand factor multimerase

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ATA770/96 1996-04-29
ATA769/96 1996-04-29
AT76996A AT404359B (en) 1996-04-29 1996-04-29 Purified multimerase
AT77096A AT404554B (en) 1996-04-29 1996-04-29 Pharmaceutical preparation

Publications (2)

Publication Number Publication Date
WO1997041206A2 WO1997041206A2 (en) 1997-11-06
WO1997041206A3 true WO1997041206A3 (en) 1997-12-04

Family

ID=25593864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/002131 Ceased WO1997041206A2 (en) 1996-04-29 1997-04-25 Von willebrand factor multimerase

Country Status (10)

Country Link
US (1) US6068838A (en)
EP (1) EP0907724B1 (en)
JP (2) JP2000508918A (en)
AT (1) ATE357510T1 (en)
CA (1) CA2253246C (en)
DE (1) DE69737500T2 (en)
DK (1) DK0907724T3 (en)
ES (1) ES2285734T3 (en)
PT (1) PT907724E (en)
WO (1) WO1997041206A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067221B2 (en) 2001-04-25 2011-11-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Von Willebrand factor (vWF)-cleaving protease

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU744873B2 (en) 1996-11-06 2002-03-07 Regents Of The University Of California, The Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods of the use thereof
US6593456B1 (en) * 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
US20050191661A1 (en) * 1996-11-06 2005-09-01 Tetsuya Gatanaga Treatment of inflammatory disease by cleaving TNF receptors
AT405485B (en) 1997-05-28 1999-08-25 Immuno Ag A PHARMACEUTICAL PREPARATION CONTAINING THE VWF PROPEPTIDE
AT407750B (en) * 1999-02-19 2001-05-25 Immuno Ag METHOD FOR PRODUCING A VWF PREPARATION
CA2362483A1 (en) * 1999-02-25 2000-08-31 Bernhard Lammle Test kit for analysing factor viii-splitting protease
DE19957065B4 (en) 1999-11-26 2005-01-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Screening procedure for drugs
US20050153383A1 (en) * 2000-07-28 2005-07-14 Montgomery Robert R. Synthetic and recombinant substrates for the detecion of the von willebrand factor-cleaving protease
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
JP2008512098A (en) 2004-09-07 2008-04-24 アーケミックス コーポレイション Aptamers against von Willebrand factor and their use as treatments for thrombotic diseases
AU2005282380A1 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
AU2012255027B2 (en) 2011-05-19 2015-09-24 Takeda Pharmaceutical Company Limited Detection of circulating ADAMTS13-antibody complexes
WO2020214033A1 (en) * 2019-04-17 2020-10-22 Erasmus University Medical Center Rotterdam Papain-like cysteine peptidase medicaments and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0503991A1 (en) * 1991-03-08 1992-09-16 Centre Regional De Transfusion Sanguine De Lille Process for preparing a highly purified standardized concentrate of human von Willebrand factor on industrial scale, appropriate for therapeutic use
DE4435485C1 (en) * 1994-10-04 1996-03-21 Immuno Ag Process for obtaining high-purity von Willebrand factor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
AT389815B (en) * 1984-03-09 1990-02-12 Immuno Ag METHOD FOR INACTIVATING VARIABLE FILTERABLE DISEASERS IN BLOOD PRODUCTS
NL8500961A (en) * 1985-04-01 1986-11-03 Stichting Vrienden Van De Stic CDNA CODING FOR THE HUMANE VON WILLEBRAND FACTOR, PLASMIDS WITH SUCH CDNA CODING, RESPECTIVE FRAGMENTS, AND MICRO-ORGANISMS CONTAINING SUCH PLASMS.
AT390801B (en) * 1988-07-28 1990-07-10 Immuno Ag METHOD FOR PRODUCING LYS PLASMINOGEN
AT402891B (en) * 1991-06-20 1997-09-25 Immuno Ag METHOD FOR PRODUCING AN INACTIVATED BLOOD PRODUCT
EP0674531A1 (en) * 1992-12-16 1995-10-04 IMMUNO Aktiengesellschaft Process for preparing a virus-safe biological composition
DE4434538C2 (en) * 1993-10-06 2000-08-10 Immuno Ag Virus inactivation method in the presence of a polyether and a chaotropic agent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0503991A1 (en) * 1991-03-08 1992-09-16 Centre Regional De Transfusion Sanguine De Lille Process for preparing a highly purified standardized concentrate of human von Willebrand factor on industrial scale, appropriate for therapeutic use
DE4435485C1 (en) * 1994-10-04 1996-03-21 Immuno Ag Process for obtaining high-purity von Willebrand factor
WO1996010584A1 (en) * 1994-10-04 1996-04-11 Immuno Aktiengesellschaft Process for extracting high-purity von willebrand factor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERKOWITZ, SCOTT D. ET AL: "Sialic acid prevents loss of large von Willebrand factor multimers by protecting against amino-terminal proteolytic cleavage", BLOOD (1988), 72(5), 1790-6 CODEN: BLOOAW;ISSN: 0006-4971, 1988, XP002042010 *
FURLAN, MIHA ET AL: "Partial purification and characterization of a protease from human plasma which cleaves von Willebrand factor to fragments produced by in vivo proteolysis", BLOOD (1996), 87(10), 4223-4234 CODEN: BLOOAW;ISSN: 0006-4971, 1996, XP002042011 *
JUDITH A. DENT ET AL.: "Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 87, August 1990 (1990-08-01), WASHINGTON US, pages 6306-6310, XP002042009 *
THOMAS J. KUNICKI ET AL.: "Cleavage of human von Willebrand factor by platelet Calcium-activated protease", BLOOD, vol. 65, no. 2, February 1985 (1985-02-01), pages 352 - 356, XP002042008 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067221B2 (en) 2001-04-25 2011-11-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Von Willebrand factor (vWF)-cleaving protease

Also Published As

Publication number Publication date
JP2008289498A (en) 2008-12-04
ATE357510T1 (en) 2007-04-15
CA2253246C (en) 2010-11-02
DK0907724T3 (en) 2007-06-04
EP0907724A2 (en) 1999-04-14
DE69737500D1 (en) 2007-05-03
WO1997041206A2 (en) 1997-11-06
US6068838A (en) 2000-05-30
ES2285734T3 (en) 2007-11-16
JP2000508918A (en) 2000-07-18
EP0907724B1 (en) 2007-03-21
CA2253246A1 (en) 1997-11-06
DE69737500T2 (en) 2007-11-29
PT907724E (en) 2007-04-30

Similar Documents

Publication Publication Date Title
ATE357510T1 (en) VON WILLEBRAND FACTOR MULTIMERASE
PH31249A (en) Inhibitors of hiv protease.
WO1998024806A3 (en) Substituted oxadiazole, thiadiazole and triazole serine protease inhibitors
YU28499A (en) New aqueous medicament preparations for the production of propellent gas-free aerosols
GR3030719T3 (en) Sulfonamide inhibitors of hiv-aspartyl protease.
FI950168L (en) High-alkaline serine proteases
HU0900219D0 (en) Hiv protease inhibitor
EP0252057A3 (en) Serine protease inhibitors
FI942693A7 (en) Pyridazines as inhibitors of interleukin-1beta converting enzyme
BR9301489A (en) PROCESSES FOR THE PREPARATION OF PURIFIED ENZYME FROM A FERMENTATION BRUSH AND FOR THE PREPARATION OF PURIFIED ALKALINE PROTEASE DERIVED FROM BACILLUS ALCALOPHILUS OR LICHENFORMIS BACILLUS FROM A FERMENTATION SOIL AND USE OF A PHASE OF PHASE.
AU6794994A (en) New alkaline serine protease of paecilomyces lilacinus
CA2079077A1 (en) Tissue glue prepared by using cryoprecipitate
CA2128711A1 (en) Trypsin inhibitors
TW362096B (en) Novel piperidine derivatives and the process for preparing the same
CA2093950A1 (en) Subtilisin-like protease from aspergillus niger
CA2342985A1 (en) Hydroxamate-containing cysteine and serine protease inhibitors
CA2058948A1 (en) Processes for the recovery of naturally produced chymosin
AU4232196A (en) Suppression of proteolytic activity by dysfunctional protease formation
AU1576495A (en) Inhibitors of serine proteases, bearing a chelating group
AU4227189A (en) Cyclopeptide derivatives, usable as selective inhibitors of proteases with active serine
AU6828894A (en) Hiv protease inhibitors
ZA961225B (en) Serine protease inhibitors
AU6171594A (en) Serine protease variants having peptide ligase activity
Shin et al. Purification and characterization of metalloproteases from Pleurotus sajor-caju
WO2000015625A3 (en) Methods of making dihydropyrone hiv protease inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997921765

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2253246

Country of ref document: CA

Ref country code: CA

Ref document number: 2253246

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1997921765

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1997921765

Country of ref document: EP